ArticleBehavioural neurology2022
Medical Cannabis for Gilles de la Tourette Syndrome: An Open-Label Prospective Study.
Article in Behavioural neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 3 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Global bibliometric analysis of Tourette syndrome research (1960-2024): trends, collaborations and emerging themes.Frontiers in neurology · 2025Pooled it
- Premonitory urge in tic disorders - a scoping review.Frontiers in psychiatry · 2025Pooled it
- Efficacy of cannabis-based medicine in the treatment of Tourette syndrome: a systematic review and meta-analysis.European journal of clinical pharmacology · 2024Pooled it
- Function-Specific Localization in the Supplementary Motor Area: A Potential Effective Target for Tourette Syndrome.CNS neuroscience & therapeutics · 2025Trial
- Detecting and understanding potential stigma among medical cannabis users in Germany.BMC public health · 2025Article
- Pain in Tourette Syndrome: A Comprehensive Review.Journal of child and adolescent psychopharmacology · 2025Review
- The Use of Compounds Derived fromInternational journal of molecular sciences · 2024Review
- Therapeutic use of medical Cannabis in neurological diseases: a clinical update.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- A single-center real-life study on the use of medical cannabis in patients with dystonia.Frontiers in neurology · 2023Article
- The role of cannabinoids in neurodevelopmental disorders of children and adolescents.Revista de neurologia · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Assessing the effectiveness and tolerability of medical cannabis (MC) treatment on Gilles de la Tourette syndrome (GTS) patients. Methods: We report on an open-label, prospective study on the effect of MC on adult GTS patients. MC mode of use was decided by the treating neurologist and the patient. Results: Eighteen patients entered the study. Baseline Yale Global Tic Severity Scale- (YGTSS) Total (range 0-100) was 60.3 ± 17.1. Three patients did not reach the end of follow-up period. The most common mode of administration was smoking (80%). Following twelve weeks of treatment, a significant 38% average reduction ( Conclusions: MC treatment demonstrates good efficacy and tolerability in adult GTS patients. Predilection for smoking rather than using oil drops requires further comparative studies to evaluate the efficacy of each. Cognitive and psychiatric side effects have to be monitored and addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.